Reduced Volume and Faster Infusion Rate of Activated Prothrombin Complex Concentrate: A Phase 3b/4 Trial in Adults with Hemophilia A with Inhibitors

Bülent Zülfikar; Johnny Mahlangu; Salim Mohamed Nekkal; Cecil Ross; Noppacharn Uaprasert; Jerzy Windyga; Carmen Escuriola Ettingshausen; Bettina Ploder; Aurelia Lelli; Hanna T. Gazda

doi:10.1055/s-0044-1787781

TH Open (Jul 2024)

Reduced Volume and Faster Infusion Rate of Activated Prothrombin Complex Concentrate: A Phase 3b/4 Trial in Adults with Hemophilia A with Inhibitors

Bülent Zülfikar,
Johnny Mahlangu,
Salim Mohamed Nekkal,
Cecil Ross,
Noppacharn Uaprasert,
Jerzy Windyga,
Carmen Escuriola Ettingshausen,
Bettina Ploder,
Aurelia Lelli,
Hanna T. Gazda

Affiliations

Bülent Zülfikar: Hereditary Bleeding Disorders Unit in Oncology Institute, Istanbul University, Istanbul, Turkey
Johnny Mahlangu: Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa
Salim Mohamed Nekkal: CHU Isaad Hassani, Beni Messous, Algiers, Algeria
Cecil Ross: St John's Medical College Hospital, Bangalore, India
Noppacharn Uaprasert: Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
Jerzy Windyga: Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Carmen Escuriola Ettingshausen: Haemophilia Centre Rhein Main, Frankfurt-Mörfelden, Germany
Bettina Ploder: Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
Aurelia Lelli: PDT R&D Global Medical Affairs, Takeda Pharmaceuticals International AG, Zurich, Switzerland
Hanna T. Gazda: Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States

DOI: https://doi.org/10.1055/s-0044-1787781
Journal volume & issue: Vol. 08, no. 03
pp. e273 – e282

Abstract

Read online

Background Activated prothrombin complex concentrate (aPCC) is indicated for bleed treatment and prevention in patients with hemophilia with inhibitors. The safety and tolerability of intravenous aPCC at a reduced volume and faster infusion rates were evaluated.

Published in TH Open

ISSN: 2512-9465 (Online)
Publisher: Georg Thieme Verlag KG
Country of publisher: Germany
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://doi.org/10.1055/s-00033990

About the journal

Abstract

Keywords